Ozempic, Wegovy and Snoring: What Semaglutide Has Evidence For

Since tirzepatide was approved for obstructive sleep apnea in December 2024, a reasonable question has followed it around: does the drug I am actually on do the same thing?

For most people that drug is semaglutide — Ozempic or Wegovy. And the honest answer is narrower than you would hope.

There is no semaglutide sleep apnea trial

Semaglutide has never been tested against obstructive sleep apnea in a randomised trial with apnea severity as the endpoint. Not a small one, not an underpowered one. The trial does not exist.

That is an unusual thing to be able to say cleanly, so it is worth being precise about what it does and does not mean. It does not mean semaglutide fails to help. It means nobody has measured it directly, and anyone telling you how many events per hour it removes is extrapolating.

Two GLP-1 drugs do have apnea-specific randomised evidence, and neither of them is semaglutide.

What the two drugs with trials showed

Tirzepatide is the one with the strong result and the FDA indication. Across the two SURMOUNT-OSA trials it reduced the apnea-hypopnea index by roughly 20 to 24 events per hour more than placebo, with 42% to 50% of participants reaching remission — defined as an AHI under 5, or under 15 without symptoms.

Liraglutide, the oldest drug in the class, was tested back in 2016. The SCALE Sleep Apnea trial randomised 359 adults with obesity and moderate-to-severe apnea who were unwilling or unable to use CPAP. After 32 weeks, mean AHI fell by 12.2 events per hour on liraglutide against 6.1 on placebo — a treatment difference of 6.1 events per hour, which cleared statistical significance at P=0.015.

That difference is real and it is also small. Participants started at a mean AHI of 49.2, which is severe. Ending around 37 is an improvement that leaves you comfortably still in the severe range. Weight loss was 5.7% against 1.6% on placebo.

So within one drug class you have a 6-event difference and a 20-plus-event difference. The class is not uniform, and averaging across it hides more than it reveals. Six meta-analyses of GLP-1 receptor agonists in apnea have produced AHI reductions anywhere from 5.7 to 21.9 events per hour, which is the statistical signature of drugs and doses that are not interchangeable.

Why the mechanism still applies

Semaglutide produces substantial weight loss. Weight loss reduces apnea severity. There is no reason to think semaglutide is somehow exempt from a mechanism that operates through body composition.

And the mechanism is more specific than "weight." GLP-1 receptor agonists reduce tongue fat and parapharyngeal fat — the deposits that sit directly against the airway and make it more collapsible when the muscles relax in sleep. That is the fat that matters for snoring, not the fat on the scale. How weight actually relates to the airway.

Evidence tier 2 for semaglutide and snoring — a real, well-characterised mechanism with no direct trial behind it. Tier 1 for tirzepatide, in diagnosed moderate-to-severe apnea with obesity, and only there.

What to expect for snoring specifically

Here the evidence thins out further. None of these trials used snoring as an endpoint. They measured apnea-hypopnea index, which is a count of breathing interruptions, not loudness.

Those things move together on average and come apart constantly in individuals. Whether losing weight quiets you down depends on where your airway narrows. If the problem is fat around a collapsible pharynx, weight loss reaches it. If you snore because of a deviated septum, a long uvula or nasal valve collapse, a GLP-1 drug will do very little for the noise, because the noise was never coming from the tissue the drug changes.

This is the same reason people lose 20 kg and report their partner still elbows them nightly. It is not a failure of the drug. It is an anatomy mismatch.

The part that matters clinically

Do not treat improved snoring as evidence your apnea resolved. This is the single most consequential mistake available here. Snoring often gets quieter well before apnea normalises, and it can get quieter while apnea stays dangerous — a partially obstructed airway makes noise, a fully obstructed one goes silent.

Do not stop CPAP because you are losing weight. Even in the tirzepatide trials, one whole arm was people continuing PAP therapy, and they benefited alongside it rather than instead of it. Most participants still had measurable apnea at the end.

Get retested if you have lost significant weight. Severity is not fixed, which cuts both ways: it can fall enough to change your treatment, and you cannot know by how much without a repeat study. What a sleep test involves.

If you have never been tested and you snore, the drug question is the wrong one to be asking first. The warning signs that matter are witnessed pauses in breathing, gasping or choking arousals, waking unrefreshed after adequate hours, and daytime sleepiness that does not respond to more sleep. Any of those and the priority is a diagnosis. How to tell snoring from apnea.

So should you expect anything?

If you are taking semaglutide for weight or diabetes and you snore, a reduction in snoring is a plausible secondary benefit, not a promise, and not a reason to choose one drug over another.

If you have diagnosed moderate-to-severe apnea and obesity and you want the drug with evidence behind it for that specific problem, that drug is tirzepatide, and the conversation belongs with the clinician managing your apnea rather than with whoever prescribes your weight-loss medication.

And if what you actually want tonight is less noise, drugs are a slow answer to a fast question. The alternatives, ranked by what they are good for.